(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

KYMERA THERAPEUTICS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

KYMERA THERAPEUTICS

ST13

US500000088985233

Class

42

Filing

88985233

Registration

7176561

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

61

Latest update

03/15/2026

Trademark type

Word

Nice classes

42

Filing date

11/22/2018

Registration date

09/26/2023

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

09/26/2023

Last transaction

03/15/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

10/31/2017

First use in commerce

10/31/2017

Drawing code

4

Owner type

03

Owner location

Watertown, MA, US

Examiner

DEFORD, JEFFREY S

Law office

M60

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc.

Representatives

Lisa M. Tittemore Merchant & Gould P.C.

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Research and development of therapeutic drugs for the treatment of oncologyautoimmuneimmune-oncology and other related diseases; Research and development of pharmaceuticalsresearch and development of technology in the field of pharmaceuticals; Development of pharmaceutical preparations and medicines; Drug development and discovery; Medical research for development of therapeutic modalities for treatment of diseases; Clinical studies; Preclinical and clinical development of therapeutic products

Publications

History of USPTO decisions and trademark events.

61 publications found

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

03/13/2026

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

03/13/2026

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

03/13/2026

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

03/13/2026

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

03/13/2026

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

06/06/2025

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

06/06/2025

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

06/06/2025

EWAF

TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS

06/26/2024

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

06/26/2024

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

06/26/2024

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

06/26/2024

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

06/26/2024

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

06/26/2024

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

09/26/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

09/26/2023

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

08/23/2023

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

08/22/2023

SUPC

STATEMENT OF USE PROCESSING COMPLETE

07/31/2023

DPCC

DIVISIONAL PROCESSING COMPLETE

07/31/2023

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

07/31/2023

EISU

TEAS STATEMENT OF USE RECEIVED

07/31/2023

IUAF

USE AMENDMENT FILED

07/10/2023

ERTD

TEAS REQUEST TO DIVIDE RECEIVED

07/10/2023

DRRR

DIVISIONAL REQUEST RECEIVED

07/07/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

01/13/2023

EX4G

SOU EXTENSION 4 GRANTED

01/11/2023

EXT4

SOU EXTENSION 4 FILED

01/11/2023

EEXT

SOU TEAS EXTENSION RECEIVED

01/11/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

07/14/2022

EX3G

SOU EXTENSION 3 GRANTED

07/12/2022

EXT3

SOU EXTENSION 3 FILED

07/12/2022

EEXT

SOU TEAS EXTENSION RECEIVED

07/12/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

01/13/2022

EX2G

SOU EXTENSION 2 GRANTED

01/11/2022

EXT2

SOU EXTENSION 2 FILED

01/11/2022

EEXT

SOU TEAS EXTENSION RECEIVED

01/11/2022

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

07/14/2021

EX1G

SOU EXTENSION 1 GRANTED

07/12/2021

EXT1

SOU EXTENSION 1 FILED

07/12/2021

EEXT

SOU TEAS EXTENSION RECEIVED

07/12/2021

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

01/12/2021

TMBN

TTAB RELEASE CASE TO TRADEMARKS

12/03/2020

OP.T

OPPOSITION TERMINATED NO. 999999

12/03/2020

OP.D

OPPOSITION DISMISSED NO. 999999

11/02/2020

OP.I

OPPOSITION INSTITUTED NO. 999999

11/14/2019

OPPF

OPPOSITION PAPERS RECEIVED AT TTAB

11/07/2019

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

10/08/2019

PUBO

PUBLISHED FOR OPPOSITION

10/08/2019

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

09/18/2019

ALIE

ASSIGNED TO LIE

09/05/2019

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

09/03/2019

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

08/24/2019

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

08/23/2019

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

08/23/2019

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

02/26/2019

GNRT

NON-FINAL ACTION E-MAILED

02/26/2019

CNRT

NON-FINAL ACTION WRITTEN

02/26/2019

DOCK

ASSIGNED TO EXAMINER

02/25/2019

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

12/12/2018

NWAP

NEW APPLICATION ENTERED

11/26/2018

Continuous trademark protection

Get notified about every new filing that threatens KYMERA THERAPEUTICS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.